ID   Q8VHI0_MOUSE            Unreviewed;        29 AA.
AC   Q8VHI0;
DT   01-MAR-2002, integrated into UniProtKB/TrEMBL.
DT   01-MAR-2002, sequence version 1.
DT   09-JUL-2014, entry version 56.
DE   SubName: Full=Epidermal growth factor receptor;
DE   Flags: Fragment;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RC   STRAIN=129/Sv;
RA   Klysik J., Bradley A.;
RT   "Two new balancer inversions for mouse chromosome 11.";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF456454; AAL56615.1; -; Genomic_DNA.
DR   UniGene; Mm.420648; -.
DR   UniGene; Mm.439882; -.
DR   UniGene; Mm.8534; -.
DR   InParanoid; Q8VHI0; -.
DR   ChiTaRS; EGFR; mouse.
DR   ArrayExpress; Q8VHI0; -.
DR   Bgee; Q8VHI0; -.
DR   Genevestigator; Q8VHI0; -.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030139; C:endocytic vesicle; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0005006; F:epidermal growth factor-activated receptor activity; IEA:Ensembl.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; IEA:Ensembl.
DR   GO; GO:0000186; P:activation of MAPKK activity; IEA:Ensembl.
DR   GO; GO:0019694; P:alkanesulfonate metabolic process; IEA:Ensembl.
DR   GO; GO:0048143; P:astrocyte activation; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0016101; P:diterpenoid metabolic process; IEA:Ensembl.
DR   GO; GO:0042743; P:hydrogen peroxide metabolic process; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0010960; P:magnesium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0042698; P:ovulation cycle; IEA:Ensembl.
DR   GO; GO:0005976; P:polysaccharide metabolic process; IEA:Ensembl.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IEA:Ensembl.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0045909; P:positive regulation of vasodilation; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0033590; P:response to cobalamin; IEA:Ensembl.
DR   GO; GO:0033594; P:response to hydroxyisoflavone; IEA:Ensembl.
DR   GO; GO:0006970; P:response to osmotic stress; IEA:Ensembl.
DR   GO; GO:0006979; P:response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0070141; P:response to UV-A; IEA:Ensembl.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0043586; P:tongue development; IEA:Ensembl.
DR   GO; GO:0006412; P:translation; IEA:Ensembl.
PE   4: Predicted;
KW   Receptor.
FT   NON_TER      29     29
SQ   SEQUENCE   29 AA;  2973 MW;  0ADF0EBD2D6075D1 CRC64;
     MRPSGTARTT LLVLLTALCA AGGALEEKK
//